Althera Life Sciences

Althera Pharmaceuticals, also known as Althera Life Sciences, is a specialty pharmaceutical company focused on the development and commercialization of therapies for cardiovascular and metabolic diseases. The company's primary focus has been on creating optimized combination therapies that improve patient adherence and clinical outcomes. Its lead product, Roszet, is a fixed-dose combination of rosuvastatin and ezetimibe, which was approved by the FDA in 2021 for the treatment of hyperlipidemia. Roszet addresses the need for intensive lipid-lowering therapy by combining a potent statin with a cholesterol absorption inhibitor in a single daily tablet. In May 2022, Althera was acquired by Azurity Pharmaceuticals, a leader in providing innovative medicines for patients with specific unmet needs. The acquisition integrated Althera's cardiovascular expertise and its commercialized product into Azurity's broader portfolio of specialty treatments.